Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that inserts aquaporin‑2 water channels into the duct lining, allowing more water to be reabsorbed back into the bloodstream and producing more concentrated urine.

The exact dose of Minirin is determined by the prescribing clinician based on the patient’s age, weight, severity of the condition, and response to therapy. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without deviation.

Safety data for desmopressin acetate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue that offers a longer duration of action and greater selectivity for V2 receptors compared with natural vasopressin. This results in fewer cardiovascular side effects and allows convenient nasal administration, whereas alternatives may require injection or have broader receptor activity.

Minirin nasal spray should be stored at room temperature, below 25 °C. Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain potency.

Minirin is supplied as a metered‑dose nasal spray. The patient sprays the prescribed number of sprays into each nostril, usually once or twice daily, as directed by the prescriber. Proper technique includes tilting the head slightly forward and avoiding blowing the nose immediately after dosing.

The most serious risks include severe hyponatraemia, which can lead to seizures, coma, or death, and water intoxication resulting in cerebral edema. Patients should be monitored for rapid weight gain, confusion, headache, or nausea, and serum sodium levels should be checked regularly.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin or any component of the formulation, in patients with uncontrolled hypertension, and in those with conditions predisposing them to hyponatraemia such as severe renal or hepatic impairment. Clinicians must evaluate each patient’s medical history before prescribing.